Global Liquid Biopsy Market Research Report 2022: Research vs. Clinical Liquid Biopsy / Liquid Biopsy Market by Type of Analyte

News provided by

Jan 14, 2022, 14:15 ET

DUBLIN, Jan. 14, 2022 /PRNewswire/ -- The "The World Liquid Biopsy Market 2021" report has been added to ResearchAndMarkets.com's offering.

While tissue biopsies and imaging techniques remain the current standards of care in the diagnosis of solid tumors, they have risks and limitations and limitations, some of which can be overcome by the use of liquid biopsy in clinical oncology, as an alternative or complementary technique to the current standards of care.

This report contains up-to-date information and useful data points for business planning:

Research vs. Clinical Liquid Biopsy
The Market for Liquid Biopsy by Region
The Market for Liquid Biopsy Market by Type of Analyte
The Market for CTC-based Liquid Biopsy
The Market for ctDNA-based Liquid Biopsy
The Market for EV and Exosome-based Liquid Biopsy
The Market for Multi-Analyte-based Liquid Biopsy
The Market for Other Liquid Biopsy
Liquid Biopsy Market by Type of Cancer (Breast, Lung, Colorectal, Ovarian, Prostate, Pan-Cancer, Other Cancer)
Selected ctDNA-based Liquid Biopsy Tests in Development
Selected Market-Available CTC-based Liquid Biopsy Tests, 2021
Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2021

Liquid biopsy testing has many potential applications in aspects of clinical oncology, including:

Early detection and diagnosis/screening
Alternative testing method when tissue biopsy is difficult/impossible, or when the primary site of metastatic disease is unknown
Therapy personalization and monitoring - by molecular characterization of a patient's disease, clinicians can select the optimal course of therapy and monitor efficacy over time, as well as quickly react to adjust therapy should treatment resistance arise
Disease monitoring - to observe disease progression, tumor evolution, residual disease, and early detection of recurrence
Prognosis of disease

Key Topics Covered:

CHAPTER 1: EXECUTIVE SUMMARY
INTRODUCTION
LIQUID BIOPSY TECHNOLOGIES
INDUSTRY STRUCTURE
LIQUID BIOPSY MARKET REVENUES AND FORECAST

CHAPTER 2: LIQUID BIOPSY TECHNOLOGIES
INTRODUCTION
CURRENT MAJOR LIQUID BIOPSY TECHNOLOGIES

CHAPTER 3: CIRCULATING TUMOR DNA (CTDNA) LIQUID BIOPSY
INTRODUCTION
ADVANTAGES AND LIMITATIONS OF CTDNA IN LIQUID BIOPSY
CURRENT CTDNA-BASED LIQUID BIOPSY TESTS

Biocartis
Biocept
Biodesix
CellMax Life
Circulogene
Diacarta
Epigenomics
Foundation Medicine (Roche)
Guardant Health
Inivata (Neogenomics)
LungLife AI
Myriad Genetics
NeoGenomics
OncoDNA
Personal Genomic Diagnostics
QIAGEN
Resolution Biosciences
Roche Diagnostics
Sysmex-Inostics
Tempus

CTDNA-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT

Exact Sciences
Freenome
GRAIL
Neogenomics

CHAPTER 4: CIRCULATING TUMOR CELLS (CTCS) LIQUID BIOPSY
INTRODUCTION
CHALLENGES IN THE DEVELOPMENT OF CTC-BASED LIQUID BIOPSY TESTS
CTC-BASED LIQUID BIOPSY TESTS

Adaptive Biotechnologies
Biocept
CellMax Life
Epic Sciences
GILUPI
LungLife AI
Menarini-Silicon Biosystems
QIAGEN

CTC-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT

ANGLE
Epic Sciences
Liquid Biotech USA

CHAPTER 5: EXTRACELLULAR VESICLES AND OTHER LIQUID BIOPSY
INTRODUCTION
LIQUID BIOPSY TESTS BASED ON EXTRACELLULAR VESICLES/OTHER ANALYTES

Aspira Women's Health (formerly Vermillion)
Biodesix
Exosome Diagnostics
Hologic
MDxHealth

EXTRACELLULAR VESICLE/OTHER ANALYTE-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT

Circulogene
OncoCyte
Resolution Biosciences
VolitionRx

CHAPTER 6: MULTI-ANALYTE LIQUID BIOPSY TESTS
LIQUID BIOPSY TESTS BASED ON MULTIPLE ANALYTES

Biocept
Biodesix
Foundation Medicine (Roche)
LungLife AI
NeoGenomics
OncoDNA

MULTIPLE ANALYTE-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT

Exact Sciences
Freenome
GRAIL
LungLife AI

CHAPTER 7: LIQUID BIOPSY TESTS FOR RESEARCH USE ONLY
INTRODUCTION
LIQUID BIOPSY TESTS FOR RESEARCH USE ONLY

Agena Bioscience
ANGLE
DiaCarta
Exosome Diagnostics
Guardant Health
Natera
QIAGEN

CHAPTER 8: LIQUID BIOPSY INDUSTRY ANALYSIS
TIERS OF COMPETITION
COMPETITIVE FACTORS
SIGNIFICANT MARKET TRENDS

Personalized Medicine
Increasing Global Life Expectancy
New Liquid Biopsy Products
Increasing Accessibility of Genetic Testing
Regulatory Hurdles
Third-Party Payor Coverage
Demonstrated Clinical Utility
Incidence Rates of Specific Cancers

COMPETITORS NO LONGER IN THE LIQUID BIOPSY MARKET

CHAPTER 9: LIQUID BIOPSY MARKET
MARKET OVERVIEW
MARKET FORECAST

CHAPTER 10: MARKET BY ANALYTE CIRCULATING TUMOR DNA

CIRCULATING TUMOR CELLS
EXTRACELLULAR VESICLES AND OTHER ANALYTES
MULTIPLE ANALYTES

Market Overview
Applications
Technologies
Specimens
Revenue Forecast

CHAPTER 11: MARKET BY APPLICATION
THERAPY GUIDANCE AND MONITORING
DIAGNOSIS/SCREENING
DISEASE PROGNOSIS

Market Overview
Revenue Forecast

CHAPTER 12: MARKET BY CANCER TYPE
BREAST CANCER
COLORECTAL CANCER
LUNG CANCER
OVARIAN CANCER
PROSTATE CANCER
OTHER CANCERS: Including bladder, gastrointestinal, pancreatic, renal, melanoma and hematological malignancies.

Market Overview
Revenue Forecast

PAN-CANCER TESTS

Market Overview
Revenue Forecast

CHAPTER 13: LIQUID BIOPSY COMPANY PROFILES
TOP TEN COMPANIES IN THE LIQUID BIOPSY MARKET

Companies Mentioned

Adaptive Biotechnologies
Agena Bioscience, Inc.
Angle, plc
Aspira Women'S Health
Biocartis Group Nv
Biocept, Inc.
Biodesix
Cellmax Life
Circulogene
Diacarta, Inc.
Epic Sciences
Epigenomics AG
Exact Sciences
Exosome Diagnostics, Inc.
Foundation Medicine, Inc. (Roche)
Freenome, Inc.
Gilupi GmbH
Grail (Illumina)
Guardant Health, Inc.
Hologic
Lunglife Ai (Formerly Cynvenio Biosystems)
Mdxhealth
Menarini-Silicon Biosystems, Spa
Myriad Genetics, Inc.
Natera, Inc.
Neogenomics Laboratories, Inc.
Oncocyte Corporation
Oncodna S.A.
Oncimmune
Personal Genome Diagnostics
Predicineq2 Solutionsqiagen N.V.
Cell-Free Dna Technologies
Ctc Technologies
Exosome and Mirna Technologies
Resolution Biosciences (Agilent)
Roche Diagnostics
Stagezero Life Sciences
Sysmex-Inostics, Inc.
Tempus
Veracyte
Volitionrx

For more information about this report visit https://www.researchandmarkets.com/r/9iu3nb

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets